Vaxfab Enterprises to Raise Up to ₹45 Crore via Rights Issue of Equity Shares

Key numbers

Issue Size	₹45.00 CrRights Issue Max
Market Cap	₹153.62 CrSmall Cap
1-Year Return	93.25%Stock Performance
RSI	51.11Neutral Zone

Key highlights

• Board approval for raising funds not exceeding ₹45.00 crore through a rights issue
• Issuance of equity shares with a face value of ₹10.00 each
• Constitution of a three-member Rights Issue Committee to manage the process
• Approval of the Draft Letter of Offer to be filed with BSE Limited
• Record date for eligible shareholders to be notified at a subsequent date
• Fundraise to comply with SEBI (ICDR) and SEBI (LODR) Regulations, 2015

Details of the Fundraise

Vaxfab Enterprises Ltd has sanctioned the issuance and allotment of equity shares to its existing shareholders on a rights basis. The total value of the issue is capped at ₹45.00 crore, with each share carrying a face value of ₹10.00. The board has authorized the newly formed Rights Issue Committee to determine the final pricing and the rights entitlement ratio at a later stage.

This committee will oversee the preparation and filing of the Draft Letter of Offer with BSE Limited, ensuring compliance with the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018.

Committee Formation and Governance

• The Rights Issue Committee is chaired by Mr. Ravindra Ashokbhai Joshi.
• Mr. Jinang Dineshkumar Shah and Ms. Juhi Sawajani serve as committee members.
• The committee is empowered to appoint various intermediaries, including lead managers and legal counsel.
• They are authorized to handle all statutory filings and regulatory correspondences required for the issuance.
• The record date for determining shareholder eligibility will be announced following further committee deliberations.

Financial and Market Context

The company, which operates in the commodity trading and distribution sector, currently holds a market capitalization of ₹153.62 crore. While Vaxfab Enterprises reported an annual operating revenue of ₹94.11 crore for the last fiscal year, reflecting a 67.74% year-on-year growth, its most recent quarterly results as of June 2026 showed a net loss of ₹5.84 crore. The stock has exhibited a significant 1-year price increase of 93.25%, trading at a Price-to-Book value of 5.99.

This rights issue follows a period of high volatility, with the stock price ranging from a 52-week low of ₹32.5 to a high of ₹72.

Industry Perspective

Within the commercial services and supplies sector, funding trends have seen a shift toward rights issues as a means for small-cap entities to deleverage or fund working capital requirements without immediate debt obligations. The industry P/E ratio stands at 47.58, whereas Vaxfab Enterprises currently has a negative TTM P/E due to recent losses. The company's promoter holding is reported at zero percent, with minimal institutional participation of 0.04%.

This capital raise represents a strategic effort to mobilize resources from the existing shareholder base to support the company's operational trajectory.

Vaxfab Enterprises · financial snapshot

Share price	₹65.32
Market capitalisation	₹153.62
Revenue (annual)	₹94.11
Net profit (annual)	₹3.64
P/E (TTM)	-31.71×Sector 41.15×
Promoter holding	0%0.00% QoQ
FII holding	0.04%Current quarter

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.